Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece

Published:2017-06-12 Issue:9 Volume:37 Page:833-844
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Gourzoulidis George,Kourlaba Georgia,Kakisis John,Matsagkas Mitiadis,Giannakoulas George,Gourgoulianis Konstantinos I.,Vassilakopoulos Theodoros,Maniadakis Nikos

Funder

This study was funded by Bayer Hellas

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/article/10.1007/s40261-017-0540-1/fulltext.html

Reference59 articles.

1. Moheimani F, Jackson DE. Venous thromboembolism: classification, risk factors, diagnosis, and management. ISRN Hematol. 2011;2011:124610.

2. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. JTH. 2005;3(8):1611–7.

3. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. New Engl J Med. 2004;350(22):2257–64.

4. Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. J Med Econ. 2011;14(1):65–74.

5. Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy. 2009;29(8):943–53.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimation of the outpatient anticoagulation cost for pulmonary embolism in Greece;Pneumon;2024-06-05

2. Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece;Value in Health Regional Issues;2023-07

3. Cost‐of‐Illness Analysis of Long‐Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry;Journal of the American Heart Association;2022-10-18

4. Cost-effectiveness of Venous Thromboembolism Prophylaxis After Hospitalization in Patients With Inflammatory Bowel Disease;Inflammatory Bowel Diseases;2021-09-30

5. A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia;ClinicoEconomics and Outcomes Research;2021-09